Company Description
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States.
Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform.
The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202 for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II.
It also develops RGX-111 for the treatment of mucopolysaccharidosis type I. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies.
Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 and with Nippon Shinyaku Co., Ltd. to develop RGX-121 and RGX-111 outside the United States.
REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.
| Country | United States |
| Founded | 2008 |
| IPO Date | Sep 17, 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 371 |
| CEO | Curran Simpson |
Contact Details
Address: 9804 Medical Center Drive Rockville, Maryland 20850 United States | |
| Phone | 240 552 8181 |
| Website | regenxbio.com |
Stock Details
| Ticker Symbol | RGNX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001590877 |
| CUSIP Number | 75901B107 |
| ISIN Number | US75901B1070 |
| Employer ID | 47-1851754 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Curran M. Simpson M.S. | President, Chief Executive Officer and Director |
| Patrick J. Christmas II, J.D. | Executive Vice President and Chief Strategy and Legal Officer |
| Dr. Stephen Pakola M.D. | Executive Vice President and Chief Medical Officer |
| Mitchell Chan M.B.A. | Executive Vice President and Chief Financial Officer |
| Craig Malzahn | Executive Vice President of Product Development and Chief Technology Officer |
| Dr. Olivier Danos Ph.D. | Executive Vice President and Chief Scientific Officer |
| Shiva G. Fritsch | Chief Communications and People Officer |
| Dr. Ram Palanki Pharm.D. | Executive Vice President and Chief Commercial Officer |
| Nina Hunter | SVice President of Global Regulatory Strategy and Quality |
| Dr. Jahannaz Dastgir D.O. | Clinical Development Lead |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 14, 2026 | ARS | Filing |
| Apr 14, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 14, 2026 | DEF 14A | Other definitive proxy statements |
| Apr 3, 2026 | PRE 14A | Other preliminary proxy statements |
| Mar 27, 2026 | SCHEDULE 13G/A | Filing |
| Mar 20, 2026 | 8-K | Current Report |
| Mar 10, 2026 | 144 | Filing |
| Mar 5, 2026 | 10-K | Annual Report |
| Mar 5, 2026 | 8-K | Current Report |
| Feb 12, 2026 | 424B5 | Filing |